Shire's Gaucher drug has edge over rival in trial

LONDON Thu Jun 28, 2012 4:04pm IST

Related Topics

Stocks

   

LONDON (Reuters) - Shire's Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi's Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.

The findings from the Shire-sponsored study, made public at a European Working Group on Gaucher Disease in Paris, may help Shire differentiate its product from Cerezyme, which is made by Sanofi's Genzyme unit.

Gaucher disease is a rare genetic disorder affecting some 10,000 patients worldwide. Patients with the disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

For many years Genzyme dominated the Gaucher market with its drug Cerezyme, at one point the most expensive drug in the world costing more than $200,000 a year.

But competition is now increasing. In addition to Vpriv, there is also another Gaucher drug called Elelyso from Protalix Biotherapeutics and Pfizer, which was approved by U.S. regulators in May but was rebuffed in Europe last week.

Ari Zimran of the Hebrew University and Hadassah Medical School, Jerusalem, said the study results showed Vpriv was effective in treating key markers of Gaucher-related bone disease.

Clinically and statistically significant improvements in bone measurements were seen at nine months of treatment with Vpriv but not with Cerezyme.

(Reporting by Ben Hirschler)

FILED UNDER:

Fighting Ebola

Reuters Showcase

Markets Weekahead

Markets Weekahead

Column - Caution advised in a trader’s market  Full Article 

Reuters Poll

Reuters Poll

RBI seen holding rates steady on Tuesday, minority of analysts expect cut  Full Article 

GDP Revised

GDP Revised

Economic growth revised up by almost 50 percent  Full Article 

Australian Open

Australian Open

Hingis wins Australian Open mixed doubles title with Paes   Full Article 

Houston's Daughter

Houston's Daughter

Bobbi Kristina Brown revived after found unresponsive in tub  Full Article 

India Art Fair

India Art Fair

Art fair turns India's capital into art hub.  Full Article 

Movie Review

Movie Review

"Rahasya" is an ode to Agatha Christie.  Full Article 

Review: Hawaizaada

Review: Hawaizaada

Movie Review: Hawaizaada  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage